CARLSBAD, Calif., Oct. 23 /PRNewswire/ -- GenVault Corporation, the leader in ambient temperature biosample management for genomic discovery, medicine and identification, today announced that David Wellis, Ph.D., GenVault's President and CEO, will be presenting at the BIOCOM Investor Conference taking place on October 26th and 27th in La Jolla, CA.
During the presentation, Dr. Wellis will provide an overview of the company together with recent customer, technical and strategic developments that have enabled GenVault to target the broader life sciences transport and storage markets. The major advantages of GenVault's technologies are the reduction of cost, waste and complexity associated with traditional biosample management in the academic and commercial sectors of the life sciences marketplace.
The following are specific details of GenVault's presentation at the conference:
BIOCOM Investor Conference
Date: Monday, October 26th, 2009
Time: 4:00pm (Track 2)
Location: Hyatt Regency La Jolla
Room: Aventine Ballroom, Room B
GenVault is the global leader in providing risk free biosample workflow, transport, and storage solutions for genomic medicine, discovery and identification. Today, GenVault is empowering pharmaceutical companies, medical centers, academic institutions and law enforcement agencies to more fully leverage the rapidly growing genomics industry. As a scalable, reliable and environmentally friendly alternative to traditional freezers and DNA purification systems, the company's dry-state platform enables the extraction, preservation, recovery, and distribution of biosamples at ambient temperature. Future systems will also accommodate proteins and RNA to provide a comprehensive solution. From GenPlates to the Dynamic Archive, GenVault is continuously developing and refining best practices biosample management and preservation
|SOURCE GenVault Corporation|
Copyright©2009 PR Newswire.
All rights reserved